CA2428799A1 - Combination therapy for lowering and controlling intraocular pressure - Google Patents
Combination therapy for lowering and controlling intraocular pressure Download PDFInfo
- Publication number
- CA2428799A1 CA2428799A1 CA002428799A CA2428799A CA2428799A1 CA 2428799 A1 CA2428799 A1 CA 2428799A1 CA 002428799 A CA002428799 A CA 002428799A CA 2428799 A CA2428799 A CA 2428799A CA 2428799 A1 CA2428799 A1 CA 2428799A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- integer
- cooh
- bond
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Angiostatic agents and another IOP lowering compound are combined in ophthalmic compositions to treat glaucoma and ocular hypertension. Methods for treating glaucoma and ocular hypertension are also disclosed.
Description
COMBINATION THERAPY FOR LOWERING AND CONTROLLING
INTRAOCULAR FRESSURE
The present invention relates generally to the field of ophthalmology. In particular, the invention relates to the treatment of glaucoma using a combination of an angiostatic agent which lowers intraocular pressure (TOP) and a second IOP
lowering compound.
Background of the Invention Although the underlying causes of glaucoma are not understood at this time, glaucoma is characterized by damage to the optic nerve, accompanied by a decrease in the normal visual field. One early warning sign of possible glaucomatous visual field loss is elevated IOP.
There are angiostatic agents which are known to lower IOP, see, for example, U.S. Patent Nos., 4,876,250 and 5,371,078. These compounds are very effective in controlling ocular hypertension, but they usually exhibit a slow onset of action; that is, it can take several weeks before an IOP lowering effect is seen.
Other known IOP controlling agents, such as miotics, sympathomemetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins are immediately effective in lowering TOP.
The compositions of the present invention contain an angiostatic agent which provides effective, long duration control of IOP and a second IOP lowering compound to provide immediate control of a patient's elevated IOP. This combination is more effective in that a patient's IOP can be lowered and controlled with less IOP
spiking.
In addition, the effectiveness of the combination is at least additive because the 3o angiostatic agents Lower IOP via a different mechanism than any of the second IOP
lowering compounds described in this invention.
Summary of the Invention The present invention is directed to compositions useful in the treatment of glaucoma and ocular hypertension. 'The compositions contain a combination of at least one angiostatic agent and at least one other compound which lowers IOP
("second agent"). The compositions are used to lower and control IOP by topical application to a patient's affected eye(s).
Detailed Description of the Invention The development of blood vessels for the purpose of sustaining viable tissue is known as angiogenesis or neovascularization. Agents which inhibit neovascularization are known by a variety of terms such as angiostatic, angiolytic, or angiotropic agents. In addition, it has been demonstrated that many angiostatic agents have significant IOP lowering activity, CIark et al., IOVS 35 (Suppl.): 1057, 1994.
For purposes of this specification, the term "angiostatic agent" means compounds which inhibit new blood vessel formation as well as lower andlor control intraocular pressure associated with glaucoma or ocular hypertension.
Without intending to be bound by any theory, it is believed that angiostatic agents act to control intraocular pressure by inhibiting the accumulation or stimulating the dissolution of amorphous extracellular material in the trabecular meshwork of the eye. The presence of this amorphous extracellular material alters the integrity of the healthy trabecular meshwork and is a symptom associated with primary open angle glaucoma (POAG). It is not well understood why this amorphous extracellular material builds up in the trabecular meshwork of persons suffering. from POAG.
However, it has been found that the amorphous extracellular material is generally composed of glycosaminogIycans (GAGS) and basement membrane material; see, Ophthalmology, Vol. 90, No.7 (July 1983); Mayo Clirr. Proc, Vo1.61, pp.59-67 (Jan.1986); and Pediat. Neurosci. Vo1.12, pp.240-251 (1985-86). When these materials build up in the trabecular meshwork, the aqueous humor, normally present in the anterior chamber of the eye, cannot leave this chamber through its normal route (the trabecular meshwork) at its normal rate. Therefore, a normal volume of aqueous humor is produced by the ciliary processes of the eye and introduced into the anterior chamber, but its exit through the trabecular meshwork is abnormally slow.
'This results in a buildup of pressure in the eye, ocular hypertension, which can translate into pressure on the optic nerve. The ocular hypertension so generated can lead to blindness due to damage to the optic nerve.
INTRAOCULAR FRESSURE
The present invention relates generally to the field of ophthalmology. In particular, the invention relates to the treatment of glaucoma using a combination of an angiostatic agent which lowers intraocular pressure (TOP) and a second IOP
lowering compound.
Background of the Invention Although the underlying causes of glaucoma are not understood at this time, glaucoma is characterized by damage to the optic nerve, accompanied by a decrease in the normal visual field. One early warning sign of possible glaucomatous visual field loss is elevated IOP.
There are angiostatic agents which are known to lower IOP, see, for example, U.S. Patent Nos., 4,876,250 and 5,371,078. These compounds are very effective in controlling ocular hypertension, but they usually exhibit a slow onset of action; that is, it can take several weeks before an IOP lowering effect is seen.
Other known IOP controlling agents, such as miotics, sympathomemetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins are immediately effective in lowering TOP.
The compositions of the present invention contain an angiostatic agent which provides effective, long duration control of IOP and a second IOP lowering compound to provide immediate control of a patient's elevated IOP. This combination is more effective in that a patient's IOP can be lowered and controlled with less IOP
spiking.
In addition, the effectiveness of the combination is at least additive because the 3o angiostatic agents Lower IOP via a different mechanism than any of the second IOP
lowering compounds described in this invention.
Summary of the Invention The present invention is directed to compositions useful in the treatment of glaucoma and ocular hypertension. 'The compositions contain a combination of at least one angiostatic agent and at least one other compound which lowers IOP
("second agent"). The compositions are used to lower and control IOP by topical application to a patient's affected eye(s).
Detailed Description of the Invention The development of blood vessels for the purpose of sustaining viable tissue is known as angiogenesis or neovascularization. Agents which inhibit neovascularization are known by a variety of terms such as angiostatic, angiolytic, or angiotropic agents. In addition, it has been demonstrated that many angiostatic agents have significant IOP lowering activity, CIark et al., IOVS 35 (Suppl.): 1057, 1994.
For purposes of this specification, the term "angiostatic agent" means compounds which inhibit new blood vessel formation as well as lower andlor control intraocular pressure associated with glaucoma or ocular hypertension.
Without intending to be bound by any theory, it is believed that angiostatic agents act to control intraocular pressure by inhibiting the accumulation or stimulating the dissolution of amorphous extracellular material in the trabecular meshwork of the eye. The presence of this amorphous extracellular material alters the integrity of the healthy trabecular meshwork and is a symptom associated with primary open angle glaucoma (POAG). It is not well understood why this amorphous extracellular material builds up in the trabecular meshwork of persons suffering. from POAG.
However, it has been found that the amorphous extracellular material is generally composed of glycosaminogIycans (GAGS) and basement membrane material; see, Ophthalmology, Vol. 90, No.7 (July 1983); Mayo Clirr. Proc, Vo1.61, pp.59-67 (Jan.1986); and Pediat. Neurosci. Vo1.12, pp.240-251 (1985-86). When these materials build up in the trabecular meshwork, the aqueous humor, normally present in the anterior chamber of the eye, cannot leave this chamber through its normal route (the trabecular meshwork) at its normal rate. Therefore, a normal volume of aqueous humor is produced by the ciliary processes of the eye and introduced into the anterior chamber, but its exit through the trabecular meshwork is abnormally slow.
'This results in a buildup of pressure in the eye, ocular hypertension, which can translate into pressure on the optic nerve. The ocular hypertension so generated can lead to blindness due to damage to the optic nerve.
It is believed that the angiostatic agents function in the trabecular meshwork in a similar manner as shown by Ingber, et al., wherein it was shown that angiostatic steroids caused dissolution of the basement membrane scaffolding using a chick embryo neovascularization model; Endocrinology, 119, pp.1768-1775 (1986). It is believed that angiostatic agents prevent the accumulation, or promote the dissolution of, amorphous extracellular materials in the trabecular meshwork by inhibiting the formation of basement membrane materials and glycosaminoglycans. Thus, by preventing the development of these materials or promoting their dissolution, the normal integrity of the trabecular meshwork is retained and aqueous humor may flow l0 through the trabecular meshwork at normal rates. As a result, the intraocular pressure of the eye is controlled.
Preferred angiostatic agents are represented by the following structures:
R~ R2S R~ R2'S
Rro R3 RIO
R~ a R j R
R4~ _ ~ ~ ' ~ ' io ~ a Rf 3 0_ _ RS R!3 15 Structure [A] Structure [B) wherein Rl is H, -CH3 or -C2H5;
R2 is F, Cg-C 11 double bond, Cg-C 11 epoxy, H or Cl;
R3 is H, OR26, OC(=0)R27, halogen, C9-Cl1 double bond, Cg-C11 epoxy, =0, -OH, 20 -0-alkyl(Cl-C12), -OC(=0)alkyl(C1-C1~), -OC(=0)ARYL, -OC(=0)N(R)~ or -OC(=0)OR7, wherein ARYL is furyl, thienyl, pyrrolyl, or pyridyl and each of said moieties is optionally substituted with one or two (C 1-Cq.)alkyl groups, or ARYL is -(CH2)~-phenyl wherein f is 0 to 2 and the phenyl ring is optionally substituted with 1 to 3 groups selected from chlorine, fluorine, broriline, alkyl(Cl-C3), alkoxy(Cl-C3), 25 thioalkoxy-(Cl-C3), C13C-, F3C-, -NH2 and -NHCOCH3 and R is hydrogen, alkyl (C1-C4), or phenyl and each R can be the same or different, and R7 is ARYL as herein defined, or alkyl(C 1-C 1 ~);
R4 is H, CH3, CI or F;
RS is H, OH, F, Cl, Br, CH3, phenyl, vinyl or allyl;
30 R6 is H or CH3;
R9 is CH2CH~OR26, CH2CH20C(=0)R27> H, OH, CH3, F, =CH2, CH2C(=0)OR~g~, OR26, 0(C=0)R27 or 0(C=0)CH2(C=0)OR26 R1 p is -C CH, -CH=CH2, halogen, CN, N3, OR26, OC(=0)R~7, H, OH, CH3 or R10 forms a second bond between positions C-16 and C-17;
35 Rl~ is H or forms a double bond with Rl or RI4;
R13 is halogen, OR~6, OC(=0)R27, NHS, NHR26, NHC(=0)R27, N(R26)2~
NC(=0)R27, N3, H, -OH, =0, -0-P(=0)(OH)2, or -0-C(=0)-(CH2)tCOOH where t is an integer from 2 to 6;
R~ R2S R~ R2'S
Rro R3 RIO
R~ a R j R
R4~ _ ~ ~ ' ~ ' io ~ a Rf 3 0_ _ RS R!3 15 Structure [A] Structure [B) wherein Rl is H, -CH3 or -C2H5;
R2 is F, Cg-C 11 double bond, Cg-C 11 epoxy, H or Cl;
R3 is H, OR26, OC(=0)R27, halogen, C9-Cl1 double bond, Cg-C11 epoxy, =0, -OH, 20 -0-alkyl(Cl-C12), -OC(=0)alkyl(C1-C1~), -OC(=0)ARYL, -OC(=0)N(R)~ or -OC(=0)OR7, wherein ARYL is furyl, thienyl, pyrrolyl, or pyridyl and each of said moieties is optionally substituted with one or two (C 1-Cq.)alkyl groups, or ARYL is -(CH2)~-phenyl wherein f is 0 to 2 and the phenyl ring is optionally substituted with 1 to 3 groups selected from chlorine, fluorine, broriline, alkyl(Cl-C3), alkoxy(Cl-C3), 25 thioalkoxy-(Cl-C3), C13C-, F3C-, -NH2 and -NHCOCH3 and R is hydrogen, alkyl (C1-C4), or phenyl and each R can be the same or different, and R7 is ARYL as herein defined, or alkyl(C 1-C 1 ~);
R4 is H, CH3, CI or F;
RS is H, OH, F, Cl, Br, CH3, phenyl, vinyl or allyl;
30 R6 is H or CH3;
R9 is CH2CH~OR26, CH2CH20C(=0)R27> H, OH, CH3, F, =CH2, CH2C(=0)OR~g~, OR26, 0(C=0)R27 or 0(C=0)CH2(C=0)OR26 R1 p is -C CH, -CH=CH2, halogen, CN, N3, OR26, OC(=0)R~7, H, OH, CH3 or R10 forms a second bond between positions C-16 and C-17;
35 Rl~ is H or forms a double bond with Rl or RI4;
R13 is halogen, OR~6, OC(=0)R27, NHS, NHR26, NHC(=0)R27, N(R26)2~
NC(=0)R27, N3, H, -OH, =0, -0-P(=0)(OH)2, or -0-C(=0)-(CH2)tCOOH where t is an integer from 2 to 6;
Rlq, is H or forms a double bond with R12;
R15 is H, =0 or -OH;
and R~3 with R10 forms a cyclic phosphate;
wherein R9 and R15 have the meaning defined above;
or wherein R23 is -OH, O-C(=0)-Rl 1, -OP(0)-(OH)~, or -O-C(=0)-(CH2)tCOOH
wherein t is an integer from 2 to 6; and Rl 1 is -Y-(CH2)ri X-(CH~)m-S03H, -Y'-(CH2)p X'-(CH~)q NR16R17 °r -Z(CH~)rQ~
wherein Y is a bond or -0-; Y' is a bond, -0-, or -S-; each of X and X' is a bond,-CON(R1 g)-, -N(Rl g)CO-, -0-, -S-, -S(O)-, or -S(02)-; R~ g is hydrogen or alkyl (C1-l0 C4); each of R16 and R17 is a lower alkyl group of from 1 to 4 carbon atoms optionally substituted with one hydroxyl or R16 and R17 taken together with the nitrogen atom to which each is attached forms a monocyclic heterocycle selected from pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or N(lower)alkyI-piperazino wherein alkyl has from 1 to 4 carbon atoms; n is an integer of from 4 to 9;
m is an integer of from 1 to 5; p is an integer of from 2 to 9; q is an integer of from I
to 5;
Z is a bond or -0-; r is an integer of from 2 to 9; and Q is one of the following:
(1) -R19-CH2COOH wherein R19 is -S-, -S(O)-, -S(O)2-, -SO~N(R20)-, or N(R~0)SO~-; and R~0 is hydrogen or lower alkyl-(C1-Cq.); with the proviso that the 2o total number of carbon atoms in R20 and (CH~)r is not greater than 10; or (2) -CO-COOH; or (3) CON(R21)CH(R2~)COOH wherein R~1 is H and R~~ is H, CH3, -GH~COOH, -CH2CH~COOH, -CH20H, -CH~SH, -CH~CH~SCH3, or -CH2Ph-OH wherein Ph-OH is p-hydroxyphenyl;
or R21 is CH3 and R~2 is H;
or R21 and R22 taken together are -CH2CH~CH~-;
or -N(R~ I )CH(R~~)COOH taken together is -NHCH~CONHCH~COOH; and pharmaceutically acceptable salts thereof;
R24 = C, C1-C2 double bond, 0;
3o R~5 = C(R15)CH2-R23, OH, OR26, OC(=0)R27, R26= COOH, C(=0)OR26, CHOHCH2OH, CHOHCH20R26, CHOHCH20C(=0)R27, CH~CH20H,CH~CH~OR~6, CHZCH20C(=0)R27, CH2CN, CH2N3, CH2NH2, CH2NHR~6, CH2N(R26)~, CH20H, CH~OR~6, CH20(C=0)R27, CH20(P=0) (OH)~, CH20(P=0) (OR~6)~ , CHZSH, CHAS-Rig, CH2SC(=0)R27, CH~NC(=0)R~7, C(=0)CHR2gOH, C(=0)CHR~gOR26, C(=0)CHR2gOC(=0)R27 or R10 and R~5 taken together may be =C(RZg)2, that is, an optionally alkyl substituted methylene group;
wherein R26 = C1-C6 (alkyl, branched alkyl, cycloalkyl, haloalkyl, aralkyl, aryl);
R27 = R26 + OR26; R2g = H, C1-C6 (alkyl, branched alkyl, cycloalkyl).
The other IOP-lowering compounds useful in the present invention, second agents, include all presently known IOP-lowering compounds, including miotics (e.g., pilocarpine, carbachol and acetylcholinesterase inhibitors); sympathomimetics (e.g., epinephrine, dipivalylepinephrine and para-amino clonidine); beta-blockers (e.g., betaxolol, levobunolol, cartelol, and timolol); prostaglandins and their analogues and derivatives (e.g., F series (such as PGF2 ), E series (such as PGE2), D series (such as to PGD2) and compounds disclosed in U.S. Patent Nos. 4,599,353; 5,093,329; and 5,321,128, and in European Patent Nos. 0215 860 B 1 and 0 299 914 B 1; and carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide, and ethoxzolamide, and compounds disclosed in U.S. Patent Nos. 5,153,192; 5,240,923; 5,378,703; and 4,797,413). The preferred IOP-lowering compounds are: timolol, betaxolol, levobetaxolol; levobunolol, carteolol, pilocarpine, carbachol, epinephrine, dipivalyl epinephrine, -methyl dipivalylepinephrine, Trusopt, latanoprost, apraclonidine, and clonidine.
The compositions contain an amount of an angiostatic agent between O.OOOI
and 10.0 percent by weight (wt%) and an amount of a second agent between 0.00001 and 10.0 wt%. Preferably, the angiostatic agent concentration is between 0.001 and 5.0 wt%, especially preferred are concentrations between 0.01 and 2.5 wt%. The second agent concentration is preferably between 0.001 and 5.0 wt%, 0.01 to 2.5 wt%
is especially preferred.
The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater 3o detail in U.S. Patent Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760.
The entire contents of these patents are incorporated herein by reference.
As used herein, the term "finely-divided drug carrier substrate" (or "DCS") means finely-divided solids, colloidal particles, or soluble polymers and/or polyelectrolytes which are capable of selective adsorption or binding with drug molecules. Examples of DCS include, but are not limited to: finely divided silica, such as fumed silica, silicates, and bentonites; ion exchange resins, which can be anionic, cationic, or non-ionic in nature; and soluble polymers, such as, alginic acid, pectin, soluble carrageenans, Carbopol~, and polystyrene sulfonic acid. In general, the DCS component is used at a level in the range of about 0.05 to about 10.0 wt%.
For particulate DCS, the average particle size diameter ranges from 1 to 20 microns.
The amount of DCS and its characteristics (e.g., amount of cross-linking, particle size) may be varied in order to produce the desired time-release profile for the chosen drug.
In addition to the above-described principal ingredients, the anti-glaucoma compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents. Examples of l0 suitable antimicrobial preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M~ and other agents equally well-known to those skilled in the art. Such preservatives, if utilized, will typically be employed in an amount between about 0.001 and about 1.0 wt%. Examples of suitable agents which may be used to adjust the tonicity or osmolality of the formulations include: sodium chloride, potassium chloride, mannitol, dextrose, glycerin, and propylene glycol. Such agents, if utilized, will typically be employed in an amount between about 0. l and about 10.0 wt%.
As will be, appreciated by those skilled in the art, the compositions may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, gels, and erodible solid ocular inserts.
The compositions are preferably aqueous suspensions or solutions.
The compositions of the present invention may also comprise non-aqueous formulations such as: substantially non-aqueous liquids substantially non-aqueous semi-solid compositions arid solid compositions or devices.
The first class, substantially non-aqueous liquids, comprise an angiostatic agent and a second agent ("drug combination") dissolved or suspended in one or more of the following: vegetable and mineral oils, such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil; triglycerides, such as the capric/caprylic triglycerides commonly used in foods and cosmetics; liquid lanolin and lanolin derivatives; and perfluorohydrocarbons.
The second class, semi-solid compositions, comprise a drug combination dissolved or suspended in one or more of the following: various types of petrolatum, such as white, yellow, red and so on; lanolin and lanolin derivatives; gelled mineral oil having a hydrocarbon base,' such as Plastibase~; petrolatum and ethylene carbonate mixtures; petrolatum in combination with surfactants and polyglycol, such as polyoxyl 40 stearate and polyethylene glycol.
The third class, solid compositions or devices, include non-erodible devices which are inserted into the conjunctiva) sac of the eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctiva) sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on). Especially preferred are the bioerodible inserts described and detailed in US 4,540,408 (Lloyd) and US 4,730,013 (Bondi et al.), wherein drug combinations of the present invention would be entrained in a non-aqueous matrix consisting essentially of polyvinyl alcohol. The entire contents of these two patents are incorporated herein by reference.
is The present invention is also directed to methods of treating glaucoma and ocular hypertension. The compositions described above are applied topically to the affected eyes) of the patient. The frequency and amount of dosage will be determined by the clinician based on various clinical factors. -The methods will typically comprise topical application of one or two drops (or an equivalent amount of a solid or semi-solid dosage form) to the affected eye one to four times per day.
The following examples are illustrative of compositions of the present inventions. Example 2 represents the preferred combination.
R15 is H, =0 or -OH;
and R~3 with R10 forms a cyclic phosphate;
wherein R9 and R15 have the meaning defined above;
or wherein R23 is -OH, O-C(=0)-Rl 1, -OP(0)-(OH)~, or -O-C(=0)-(CH2)tCOOH
wherein t is an integer from 2 to 6; and Rl 1 is -Y-(CH2)ri X-(CH~)m-S03H, -Y'-(CH2)p X'-(CH~)q NR16R17 °r -Z(CH~)rQ~
wherein Y is a bond or -0-; Y' is a bond, -0-, or -S-; each of X and X' is a bond,-CON(R1 g)-, -N(Rl g)CO-, -0-, -S-, -S(O)-, or -S(02)-; R~ g is hydrogen or alkyl (C1-l0 C4); each of R16 and R17 is a lower alkyl group of from 1 to 4 carbon atoms optionally substituted with one hydroxyl or R16 and R17 taken together with the nitrogen atom to which each is attached forms a monocyclic heterocycle selected from pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or N(lower)alkyI-piperazino wherein alkyl has from 1 to 4 carbon atoms; n is an integer of from 4 to 9;
m is an integer of from 1 to 5; p is an integer of from 2 to 9; q is an integer of from I
to 5;
Z is a bond or -0-; r is an integer of from 2 to 9; and Q is one of the following:
(1) -R19-CH2COOH wherein R19 is -S-, -S(O)-, -S(O)2-, -SO~N(R20)-, or N(R~0)SO~-; and R~0 is hydrogen or lower alkyl-(C1-Cq.); with the proviso that the 2o total number of carbon atoms in R20 and (CH~)r is not greater than 10; or (2) -CO-COOH; or (3) CON(R21)CH(R2~)COOH wherein R~1 is H and R~~ is H, CH3, -GH~COOH, -CH2CH~COOH, -CH20H, -CH~SH, -CH~CH~SCH3, or -CH2Ph-OH wherein Ph-OH is p-hydroxyphenyl;
or R21 is CH3 and R~2 is H;
or R21 and R22 taken together are -CH2CH~CH~-;
or -N(R~ I )CH(R~~)COOH taken together is -NHCH~CONHCH~COOH; and pharmaceutically acceptable salts thereof;
R24 = C, C1-C2 double bond, 0;
3o R~5 = C(R15)CH2-R23, OH, OR26, OC(=0)R27, R26= COOH, C(=0)OR26, CHOHCH2OH, CHOHCH20R26, CHOHCH20C(=0)R27, CH~CH20H,CH~CH~OR~6, CHZCH20C(=0)R27, CH2CN, CH2N3, CH2NH2, CH2NHR~6, CH2N(R26)~, CH20H, CH~OR~6, CH20(C=0)R27, CH20(P=0) (OH)~, CH20(P=0) (OR~6)~ , CHZSH, CHAS-Rig, CH2SC(=0)R27, CH~NC(=0)R~7, C(=0)CHR2gOH, C(=0)CHR~gOR26, C(=0)CHR2gOC(=0)R27 or R10 and R~5 taken together may be =C(RZg)2, that is, an optionally alkyl substituted methylene group;
wherein R26 = C1-C6 (alkyl, branched alkyl, cycloalkyl, haloalkyl, aralkyl, aryl);
R27 = R26 + OR26; R2g = H, C1-C6 (alkyl, branched alkyl, cycloalkyl).
The other IOP-lowering compounds useful in the present invention, second agents, include all presently known IOP-lowering compounds, including miotics (e.g., pilocarpine, carbachol and acetylcholinesterase inhibitors); sympathomimetics (e.g., epinephrine, dipivalylepinephrine and para-amino clonidine); beta-blockers (e.g., betaxolol, levobunolol, cartelol, and timolol); prostaglandins and their analogues and derivatives (e.g., F series (such as PGF2 ), E series (such as PGE2), D series (such as to PGD2) and compounds disclosed in U.S. Patent Nos. 4,599,353; 5,093,329; and 5,321,128, and in European Patent Nos. 0215 860 B 1 and 0 299 914 B 1; and carbonic anhydrase inhibitors (e.g., acetazolamide, methazolamide, and ethoxzolamide, and compounds disclosed in U.S. Patent Nos. 5,153,192; 5,240,923; 5,378,703; and 4,797,413). The preferred IOP-lowering compounds are: timolol, betaxolol, levobetaxolol; levobunolol, carteolol, pilocarpine, carbachol, epinephrine, dipivalyl epinephrine, -methyl dipivalylepinephrine, Trusopt, latanoprost, apraclonidine, and clonidine.
The compositions contain an amount of an angiostatic agent between O.OOOI
and 10.0 percent by weight (wt%) and an amount of a second agent between 0.00001 and 10.0 wt%. Preferably, the angiostatic agent concentration is between 0.001 and 5.0 wt%, especially preferred are concentrations between 0.01 and 2.5 wt%. The second agent concentration is preferably between 0.001 and 5.0 wt%, 0.01 to 2.5 wt%
is especially preferred.
The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater 3o detail in U.S. Patent Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760.
The entire contents of these patents are incorporated herein by reference.
As used herein, the term "finely-divided drug carrier substrate" (or "DCS") means finely-divided solids, colloidal particles, or soluble polymers and/or polyelectrolytes which are capable of selective adsorption or binding with drug molecules. Examples of DCS include, but are not limited to: finely divided silica, such as fumed silica, silicates, and bentonites; ion exchange resins, which can be anionic, cationic, or non-ionic in nature; and soluble polymers, such as, alginic acid, pectin, soluble carrageenans, Carbopol~, and polystyrene sulfonic acid. In general, the DCS component is used at a level in the range of about 0.05 to about 10.0 wt%.
For particulate DCS, the average particle size diameter ranges from 1 to 20 microns.
The amount of DCS and its characteristics (e.g., amount of cross-linking, particle size) may be varied in order to produce the desired time-release profile for the chosen drug.
In addition to the above-described principal ingredients, the anti-glaucoma compositions of the present invention may further comprise various formulatory ingredients, such as antimicrobial preservatives and tonicity agents. Examples of l0 suitable antimicrobial preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M~ and other agents equally well-known to those skilled in the art. Such preservatives, if utilized, will typically be employed in an amount between about 0.001 and about 1.0 wt%. Examples of suitable agents which may be used to adjust the tonicity or osmolality of the formulations include: sodium chloride, potassium chloride, mannitol, dextrose, glycerin, and propylene glycol. Such agents, if utilized, will typically be employed in an amount between about 0. l and about 10.0 wt%.
As will be, appreciated by those skilled in the art, the compositions may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, gels, and erodible solid ocular inserts.
The compositions are preferably aqueous suspensions or solutions.
The compositions of the present invention may also comprise non-aqueous formulations such as: substantially non-aqueous liquids substantially non-aqueous semi-solid compositions arid solid compositions or devices.
The first class, substantially non-aqueous liquids, comprise an angiostatic agent and a second agent ("drug combination") dissolved or suspended in one or more of the following: vegetable and mineral oils, such as, liquid petrolatum, corn oil, castor oil, sesame oil, and peanut oil; triglycerides, such as the capric/caprylic triglycerides commonly used in foods and cosmetics; liquid lanolin and lanolin derivatives; and perfluorohydrocarbons.
The second class, semi-solid compositions, comprise a drug combination dissolved or suspended in one or more of the following: various types of petrolatum, such as white, yellow, red and so on; lanolin and lanolin derivatives; gelled mineral oil having a hydrocarbon base,' such as Plastibase~; petrolatum and ethylene carbonate mixtures; petrolatum in combination with surfactants and polyglycol, such as polyoxyl 40 stearate and polyethylene glycol.
The third class, solid compositions or devices, include non-erodible devices which are inserted into the conjunctiva) sac of the eye and later removed, such as the Alza-type diffusion or osmotic pressure controlled polymer membranes; and bioerodible polymers which do not have to be removed from the conjunctiva) sac, such as essentially anhydrous but water soluble polymers and resins (e.g., celluloses, polycarboxylic acids, and so on). Especially preferred are the bioerodible inserts described and detailed in US 4,540,408 (Lloyd) and US 4,730,013 (Bondi et al.), wherein drug combinations of the present invention would be entrained in a non-aqueous matrix consisting essentially of polyvinyl alcohol. The entire contents of these two patents are incorporated herein by reference.
is The present invention is also directed to methods of treating glaucoma and ocular hypertension. The compositions described above are applied topically to the affected eyes) of the patient. The frequency and amount of dosage will be determined by the clinician based on various clinical factors. -The methods will typically comprise topical application of one or two drops (or an equivalent amount of a solid or semi-solid dosage form) to the affected eye one to four times per day.
The following examples are illustrative of compositions of the present inventions. Example 2 represents the preferred combination.
Ingredient Wt.
Apraclonidine HCl 0.58 5 -Pregnane-3 ,11 ,17 , 1.0 21-tetrol-20-one .
(Tetrahydrocortisol) Tyloxapol 0.01 to 0.05 Hydroxy Propyl Methylcellulose 0.5 Benzalkonium Chloride 0.01 Sodium Chloride 0.8 Edetate Disodium 0.01 NaOHIHCI q.s. pH 7.4 Purified Water q.s. 100 mL
Apraclonidine HCl 0.58 5 -Pregnane-3 ,11 ,17 , 1.0 21-tetrol-20-one .
(Tetrahydrocortisol) Tyloxapol 0.01 to 0.05 Hydroxy Propyl Methylcellulose 0.5 Benzalkonium Chloride 0.01 Sodium Chloride 0.8 Edetate Disodium 0.01 NaOHIHCI q.s. pH 7.4 Purified Water q.s. 100 mL
Ingredient wt.%
Timolol Maleate 0.68 4,9(11)Pregnadien-17 , 1.0 21-diol-3;20-dione-21-acetate Mannitol 2.4 Sodium Chloride 0.4 Carbopol 974P 0.5 Polysorbate 80 0.05 Edetate disodium 0.01 Benzalkonium chloride 0.01 NaOH q.s. pH 7.4 Purified Water q.s. 100 mL
E~'AMPLE 3 Ingredient wt.
Betaxolol HCl 0.28 17 -Ethynyl estradiol 1.00 Benzalkonium Chloride 0.01 to Mannitol 4.50 Amberlite IRP-69 0.25 Carbomer 934P 0.20 Edetate disodium O.OI
HCl/NaOH q.s. pH 7.6 Purified Water q.s. 100 mL
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Timolol Maleate 0.68 4,9(11)Pregnadien-17 , 1.0 21-diol-3;20-dione-21-acetate Mannitol 2.4 Sodium Chloride 0.4 Carbopol 974P 0.5 Polysorbate 80 0.05 Edetate disodium 0.01 Benzalkonium chloride 0.01 NaOH q.s. pH 7.4 Purified Water q.s. 100 mL
E~'AMPLE 3 Ingredient wt.
Betaxolol HCl 0.28 17 -Ethynyl estradiol 1.00 Benzalkonium Chloride 0.01 to Mannitol 4.50 Amberlite IRP-69 0.25 Carbomer 934P 0.20 Edetate disodium O.OI
HCl/NaOH q.s. pH 7.6 Purified Water q.s. 100 mL
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims (10)
1. A composition for lowering and controlling IOP comprising a pharmaceutically effective amount of both an angiostatic agent and at least one other compound which lowers IOP.
2. The composition of Claim 1 wherein the angiostatic agent is wherein R1 is H, -CH3 or -C2H5;
R2 is F, Cg-C11 double bond, Cg-CI I epoxy, H or Cl;
R3 is H, OR26, OC(=0)R~~, halogen, Cg-CI I double bond, Cg-C I I epoxy, =0, -OH, -0-alkyl(CI-CIA), -OC(=0)alkyl(CI-CIA), -OC(=0)ARYL, -OC(=0)N(R)2 or -OC(=0)OR~, wherein ARYL is furyl, thienyl, pyrrolyl, or pyridyl and each of said moieties is optionally substituted with one or two (CI-C,~)alkyl groups, or ARYL is (CH~) f-phenyl wherein f is 0 to 2 and the phenyl ring is optionally substituted with 1 to 3 groups selected from chlorine, fluorine, bromine, alkyl(CI-C3), alkoxy(CI-C3), thioalkoxy-(C1-C3), C13C-, F3C-, NH2 and -NHCOCH3 and R is hydrogen, alkyl (CI-Cq.), or phenyl and each R can be the same or different, and R~ is ARYL as herein defined, or alkyl(CI-CI2)>
R4 is H, CH3, CI or.F;
RS is H, OH, F, Cl, Br, CH3, phenyl, vinyl or allyl;
R6 is H or CH3;
R9 is CH2CH20R~6, CH~CH20C(=0)R2~, H, OH, CH3, F, =CHI, CH2C(=0)OR2g~, OR26, 0(C=0)R~~ or 0(C=0)CH2(C=0)OR26 R10 is -C CH, -CH=CH2, halogen, CN, N3, OR26, OC(=0)R27, H, OH, CH3 or R10 forms a second bond between positions C-16 and C-17;
R12 is H or forms a double bond with R1 or R14;
R13 is halogen, OR26, OC(=0)R27, NH2, NHR26; NHC(=0)R27, N(R26)2, NC(=0)R27, N3, H, -OH, =0, -0-P(=0)(OH)2, or -0-C(=0)-(CH2)t COOH where t is an integer from 2 to 6;
R14 is H or forms a double bond with R12;
R15 is H, =0 or -OH;
and R23 with R10 forms a cyclic phosphate;
wherein R9 and R15 have the meaning defined above;
or wherein R23 is -OH, O-C(=0)-R11, -OP(0)-(OH)2, or -O-C(=0}-(CH2)t COOH
wherein t is an integer from 2 to 6; arid R11 is -Y-(CH2)n-X-(CH2)m-SO3H, -Y'-(CH2)p-X'-(CH2)q-NR16R17 or -Z(CH2)r Q, wherein Y is a bond or -0-; Y' is a bond, -0-, or -S-; each of X and X' is a bond,-CON(R18)-, -N(R18)CO-, -0-, -S-, -S(O)-, or -S(02)-; R18 is hydrogen or alkyl (C1-C4); each of R16 and R17 is a lower alkyl group of from 1 to 4 carbon atoms optionally substituted with one hydroxyl or R16 and R17 taken together with the nitrogen atom to which each is attached forms a monocyclic heterocycle selected from pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or N(lower)alkyl-piperazino wherein alkyl has from 1 to 4 carbon atoms; n is an integer of from 4 to 9;
m is an integer of from 1 to 5; p is an integer of from 2 to 9; q is an integer of from 1 to 5;
Z is a bond or -0-; r is an integer of from 2 to 9; and Q is one of the following:
(1) -R19-CH2COOH wherein R19 is -S-, -S(O)-, -S(O)2-, -SO2N(R20)-, or N(R20)SO2-; and R20 is hydrogen or lower alkyl-(C1-C4); with the proviso that the total number of carbon atoms in R20 and (CH2)r is not greater than 10; or (2) -CO-COOH; or (3) CON(R21)CH(R22)COOH wherein R21 is H and R22 is H, CH3, -CH2COOH, -CH2CH2COOH, -CH2OH, -CH2SH, -CH2CH2SCH3, or -CH2Ph-OH wherein Ph-OH is p-hydroxyphenyl;
or R21 is CH3 and R22 is H;
or R21 and R22 taken together are -CH2CH2CH2-;
or -N(R21)CH(R22)COOH taken together is -NHCH2CONHCH2COOH; and pharmaceutically acceptable salts thereof;
R24 = C, C1-C2 double bond, 0;
R25 = C(R15)CH2-R23, OH, OR26, OC(=0)R27, R26, COOH, C(=0)OR26, CHOHCH2OH, CHOHCH2OR26, CHOHCH2OC(=0)R27, CH2CH2OH,CH2CH2OR26, CH2CH2OC(=0)R27, CH2CN, CH2N3, CH2NH2, CH2NHR26, CH2N(R26)2, CH2OH, CH2OR26, CH2 0(C=0)R27, CH2 0(P=0) (OH)2, CH2 0(P=0) (OR26)2, CH2SH, CH2S-R26, CH2SC(=0)R27, CH2NC(=0)R27, C(=0)CHR28OH, C(=0)CHR28OR26, C(=0)CHR28OC(=0)R27 or R10 and R25 taken together may be =C(R28)2, that is, an optionally alkyl substituted methylene group;
wherein R26 = C1-C6 (alkyl, branched alkyl, cycloalkyl, haloalkyl, aralkyl, aryl);
R27 = R26 + OR26; R28 = H, C1-C6 (alkyl, branched alkyl, cycloalkyl).
R2 is F, Cg-C11 double bond, Cg-CI I epoxy, H or Cl;
R3 is H, OR26, OC(=0)R~~, halogen, Cg-CI I double bond, Cg-C I I epoxy, =0, -OH, -0-alkyl(CI-CIA), -OC(=0)alkyl(CI-CIA), -OC(=0)ARYL, -OC(=0)N(R)2 or -OC(=0)OR~, wherein ARYL is furyl, thienyl, pyrrolyl, or pyridyl and each of said moieties is optionally substituted with one or two (CI-C,~)alkyl groups, or ARYL is (CH~) f-phenyl wherein f is 0 to 2 and the phenyl ring is optionally substituted with 1 to 3 groups selected from chlorine, fluorine, bromine, alkyl(CI-C3), alkoxy(CI-C3), thioalkoxy-(C1-C3), C13C-, F3C-, NH2 and -NHCOCH3 and R is hydrogen, alkyl (CI-Cq.), or phenyl and each R can be the same or different, and R~ is ARYL as herein defined, or alkyl(CI-CI2)>
R4 is H, CH3, CI or.F;
RS is H, OH, F, Cl, Br, CH3, phenyl, vinyl or allyl;
R6 is H or CH3;
R9 is CH2CH20R~6, CH~CH20C(=0)R2~, H, OH, CH3, F, =CHI, CH2C(=0)OR2g~, OR26, 0(C=0)R~~ or 0(C=0)CH2(C=0)OR26 R10 is -C CH, -CH=CH2, halogen, CN, N3, OR26, OC(=0)R27, H, OH, CH3 or R10 forms a second bond between positions C-16 and C-17;
R12 is H or forms a double bond with R1 or R14;
R13 is halogen, OR26, OC(=0)R27, NH2, NHR26; NHC(=0)R27, N(R26)2, NC(=0)R27, N3, H, -OH, =0, -0-P(=0)(OH)2, or -0-C(=0)-(CH2)t COOH where t is an integer from 2 to 6;
R14 is H or forms a double bond with R12;
R15 is H, =0 or -OH;
and R23 with R10 forms a cyclic phosphate;
wherein R9 and R15 have the meaning defined above;
or wherein R23 is -OH, O-C(=0)-R11, -OP(0)-(OH)2, or -O-C(=0}-(CH2)t COOH
wherein t is an integer from 2 to 6; arid R11 is -Y-(CH2)n-X-(CH2)m-SO3H, -Y'-(CH2)p-X'-(CH2)q-NR16R17 or -Z(CH2)r Q, wherein Y is a bond or -0-; Y' is a bond, -0-, or -S-; each of X and X' is a bond,-CON(R18)-, -N(R18)CO-, -0-, -S-, -S(O)-, or -S(02)-; R18 is hydrogen or alkyl (C1-C4); each of R16 and R17 is a lower alkyl group of from 1 to 4 carbon atoms optionally substituted with one hydroxyl or R16 and R17 taken together with the nitrogen atom to which each is attached forms a monocyclic heterocycle selected from pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or N(lower)alkyl-piperazino wherein alkyl has from 1 to 4 carbon atoms; n is an integer of from 4 to 9;
m is an integer of from 1 to 5; p is an integer of from 2 to 9; q is an integer of from 1 to 5;
Z is a bond or -0-; r is an integer of from 2 to 9; and Q is one of the following:
(1) -R19-CH2COOH wherein R19 is -S-, -S(O)-, -S(O)2-, -SO2N(R20)-, or N(R20)SO2-; and R20 is hydrogen or lower alkyl-(C1-C4); with the proviso that the total number of carbon atoms in R20 and (CH2)r is not greater than 10; or (2) -CO-COOH; or (3) CON(R21)CH(R22)COOH wherein R21 is H and R22 is H, CH3, -CH2COOH, -CH2CH2COOH, -CH2OH, -CH2SH, -CH2CH2SCH3, or -CH2Ph-OH wherein Ph-OH is p-hydroxyphenyl;
or R21 is CH3 and R22 is H;
or R21 and R22 taken together are -CH2CH2CH2-;
or -N(R21)CH(R22)COOH taken together is -NHCH2CONHCH2COOH; and pharmaceutically acceptable salts thereof;
R24 = C, C1-C2 double bond, 0;
R25 = C(R15)CH2-R23, OH, OR26, OC(=0)R27, R26, COOH, C(=0)OR26, CHOHCH2OH, CHOHCH2OR26, CHOHCH2OC(=0)R27, CH2CH2OH,CH2CH2OR26, CH2CH2OC(=0)R27, CH2CN, CH2N3, CH2NH2, CH2NHR26, CH2N(R26)2, CH2OH, CH2OR26, CH2 0(C=0)R27, CH2 0(P=0) (OH)2, CH2 0(P=0) (OR26)2, CH2SH, CH2S-R26, CH2SC(=0)R27, CH2NC(=0)R27, C(=0)CHR28OH, C(=0)CHR28OR26, C(=0)CHR28OC(=0)R27 or R10 and R25 taken together may be =C(R28)2, that is, an optionally alkyl substituted methylene group;
wherein R26 = C1-C6 (alkyl, branched alkyl, cycloalkyl, haloalkyl, aralkyl, aryl);
R27 = R26 + OR26; R28 = H, C1-C6 (alkyl, branched alkyl, cycloalkyl).
3. The composition of Claim 1 wherein the other compound which lowers IOP is selected from the group consisting of miotics, sympathomimetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins.
4. The composition of Claim 2 wherein the other compound which lowers IOP is selected from the group consisting of miotics, sympathomimetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins.
5. A composition for lowering and controlling IOP comprising a pharmaceutically effective amount of both 4,9(11)Pregnadien-17 ,21-diol-21-acetate and a beta-blocker selected from the group consisting of timolol, betaxolol, and levobetaxolol.
6. A method for lowering and controlling IOP which comprises administering to an affected eye, a composition comprising a pharmaceutically effective amount of both an angiostatic agent and at least one other compound which lowers IOP.
7. The method of Claim 6 wherein the angiostatic agent is Structure [A] Structure [B]
wherein R1 is H, -CH3 or -C2H5;
R2 is F, C9-C11 double bond, C9-C11 epoxy, H or Cl;
R3 is H, OR26, OC(=0)R27, halogen, C9-C11 double bond, C9-C11 epoxy, =0, -OH, -0-alkyl(C1-C12), -OC(=0)alkyl(C1-C12), -OC(=0)ARYL, -OC(=0)N(R)2 or -OC(=0)OR7, wherein ARYL is furyl, thienyl, pyrrolyl, or pyridyl and each of said moieties is optionally substituted with one or two (C1-C4)alkyl groups, or ARYL is -(CH2)f-phenyl wherein f is 0 to 2 and the phenyl ring is optionally substituted with 1 to 3 groups selected from chlorine, fluorine, bromine, alkyl(C1-C3), alkoxy(C1-C3), thioalkoxy-(C1-C3), Cl3C-, F3C-, NH2 and -NHCOCH3 and R is hydrogen, alkyl (C1-C4), or phenyl and each R can be the same or different, and R7 is ARYL as herein defined, or alkyl(C1-C12);
R4 is H, CH3, Cl or F;
R5 is H, OH, F, Cl, Br, CH3, phenyl, vinyl or allyl;
R6 is H or CH3;
R9 is CH2CH2OR26, CH2CH2OC(=0)R27, H, OH, CH3, F, =CH2, CH2C(=0)OR28,, OR26, 0(C=0)R27 or 0(C=0)CH2(C=0)OR26 R10 is -C CH, -CH=CH2, halogen, CN, N3, OR26, OC(=0)R27, H, OH, CH3 or R10 forms a second bond between positions C-16 and C-17;
R12 is H or forms a double bond with R1 or R14;
R13 is halogen, OR26, OC(=0)R27, NH2, NHR26, NHC(=0)R27, N(R26)2, NC(=0)R27, N3, H, -OH, =0, -0-P(=0)(OH)2, or -0-C(=0)-(CH2)t COOH where t is an integer from 2 to 6;
R14 is H or forms a double bond with R12;
R15 is H, =0 or -OH;
and R23 with R10 forms a cyclic phosphate;
wherein R9 and R15 have the meaning defined above;
or wherein R23 is -OH, O-C(=0)-R11, -OP(0)-(OH)2, or -O-C(=0)-(CH2)t COOH
wherein t is an integer from 2 to 6; and R11 is -Y-(CH2)n-X-(CH2)m-SO3H, -Y'-(CH2)p-X'-(CH2)q-NR16R17 or -Z(CH2)r Q, wherein Y is a bond or -0-; Y' is a bond, -0-, or -S-; each of X and X' is a bond,-CON(R18)-, -N(R18)CO-, -0-, -S-, -S(O)-, or -S(02)-; R18 is hydrogen or alkyl (C1-C4); each of R16 and R17 is a lower alkyl group of from 1 to 4 carbon atoms optionally substituted with one hydroxyl or R16 and R17 taken together with the nitrogen atom to which each is attached forms a monocyclic heterocycle selected from pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or N(lower)alkyl-piperazino wherein alkyl has from 1 to 4 carbon atoms; n is an integer of from 4 to 9;
m is an integer of from 1 to 5; p is an integer of from 2 to 9; q is an integer of from 1 to 5;
Z is a bond or -0-; r is an integer of from 2 to 9; and Q is one of the following:
(1) -R19-CH2COOH wherein R19 is -S-, -S(O)-, -S(O)2-, -SO2N(R20)-, or N(R20)SO2-; and R20 is hydrogen or lower alkyl-(C1-C4); with the proviso that the total number of carbon atoms in R20 and (CH2)r is not greater than 10; or (2) -CO-COOH; or (3) CON(R21)CH(R22)COOH wherein R21 is H and R22 is H, CH3, -CH2COOH, -CH2CH2COOH, -CH2OH, -CH2SH, -CH2CH2SCH3, or -CH2Ph-OH wherein Ph-OH is p-hydroxyphenyl;
or R21 is CH3 and R22 is H;
or R21 and R22 taken together are -CH2CH2CH2-;
or -N(R21)CH(R22)COOH taken together is -NHCH2CONHCH2COOH; and pharmaceutically acceptable salts thereof;
R24 = C, C1-C2 double bond, 0;
R25 = C(R15)CH2-R23, OH, OR26, OC(=0)R27, R26, COOH, C(=0)OR26, CHOHCH2OH, CHOHCH2OR26, CHOHCH2OC(=0)R27, CH2CH2OH,CH2CH2OR26, CH2CH2OC(=0)R27, CH2CN, CH2N3, CH2NH2, CH2NHR26, CH2N(R26)2, CH2OH, CH2OR26, CH2 0(C=0)R27, CH2 0(P=0) (OH)2, CH2 0(P=0) (OR26)2, CH2SH, CH2S-R26, CH2SC(=0)R27, CH2NC(=0)R27, C(=0)CHR28OH, C(=0)CHR28OR26, C(=0)CHR28OC(=0)R27 or R10 and R25 taken together may be =C(R28)2, that is, an optionally alkyl substituted methylene group;
wherein R26 = C1-C6 (alkyl, branched alkyl, cycloalkyl, haloalkyl, aralkyl, aryl);
R27 = R26 + OR26; R28 = H, C1-C6 (alkyl, branched alkyl, cycloalkyl).
wherein R1 is H, -CH3 or -C2H5;
R2 is F, C9-C11 double bond, C9-C11 epoxy, H or Cl;
R3 is H, OR26, OC(=0)R27, halogen, C9-C11 double bond, C9-C11 epoxy, =0, -OH, -0-alkyl(C1-C12), -OC(=0)alkyl(C1-C12), -OC(=0)ARYL, -OC(=0)N(R)2 or -OC(=0)OR7, wherein ARYL is furyl, thienyl, pyrrolyl, or pyridyl and each of said moieties is optionally substituted with one or two (C1-C4)alkyl groups, or ARYL is -(CH2)f-phenyl wherein f is 0 to 2 and the phenyl ring is optionally substituted with 1 to 3 groups selected from chlorine, fluorine, bromine, alkyl(C1-C3), alkoxy(C1-C3), thioalkoxy-(C1-C3), Cl3C-, F3C-, NH2 and -NHCOCH3 and R is hydrogen, alkyl (C1-C4), or phenyl and each R can be the same or different, and R7 is ARYL as herein defined, or alkyl(C1-C12);
R4 is H, CH3, Cl or F;
R5 is H, OH, F, Cl, Br, CH3, phenyl, vinyl or allyl;
R6 is H or CH3;
R9 is CH2CH2OR26, CH2CH2OC(=0)R27, H, OH, CH3, F, =CH2, CH2C(=0)OR28,, OR26, 0(C=0)R27 or 0(C=0)CH2(C=0)OR26 R10 is -C CH, -CH=CH2, halogen, CN, N3, OR26, OC(=0)R27, H, OH, CH3 or R10 forms a second bond between positions C-16 and C-17;
R12 is H or forms a double bond with R1 or R14;
R13 is halogen, OR26, OC(=0)R27, NH2, NHR26, NHC(=0)R27, N(R26)2, NC(=0)R27, N3, H, -OH, =0, -0-P(=0)(OH)2, or -0-C(=0)-(CH2)t COOH where t is an integer from 2 to 6;
R14 is H or forms a double bond with R12;
R15 is H, =0 or -OH;
and R23 with R10 forms a cyclic phosphate;
wherein R9 and R15 have the meaning defined above;
or wherein R23 is -OH, O-C(=0)-R11, -OP(0)-(OH)2, or -O-C(=0)-(CH2)t COOH
wherein t is an integer from 2 to 6; and R11 is -Y-(CH2)n-X-(CH2)m-SO3H, -Y'-(CH2)p-X'-(CH2)q-NR16R17 or -Z(CH2)r Q, wherein Y is a bond or -0-; Y' is a bond, -0-, or -S-; each of X and X' is a bond,-CON(R18)-, -N(R18)CO-, -0-, -S-, -S(O)-, or -S(02)-; R18 is hydrogen or alkyl (C1-C4); each of R16 and R17 is a lower alkyl group of from 1 to 4 carbon atoms optionally substituted with one hydroxyl or R16 and R17 taken together with the nitrogen atom to which each is attached forms a monocyclic heterocycle selected from pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or N(lower)alkyl-piperazino wherein alkyl has from 1 to 4 carbon atoms; n is an integer of from 4 to 9;
m is an integer of from 1 to 5; p is an integer of from 2 to 9; q is an integer of from 1 to 5;
Z is a bond or -0-; r is an integer of from 2 to 9; and Q is one of the following:
(1) -R19-CH2COOH wherein R19 is -S-, -S(O)-, -S(O)2-, -SO2N(R20)-, or N(R20)SO2-; and R20 is hydrogen or lower alkyl-(C1-C4); with the proviso that the total number of carbon atoms in R20 and (CH2)r is not greater than 10; or (2) -CO-COOH; or (3) CON(R21)CH(R22)COOH wherein R21 is H and R22 is H, CH3, -CH2COOH, -CH2CH2COOH, -CH2OH, -CH2SH, -CH2CH2SCH3, or -CH2Ph-OH wherein Ph-OH is p-hydroxyphenyl;
or R21 is CH3 and R22 is H;
or R21 and R22 taken together are -CH2CH2CH2-;
or -N(R21)CH(R22)COOH taken together is -NHCH2CONHCH2COOH; and pharmaceutically acceptable salts thereof;
R24 = C, C1-C2 double bond, 0;
R25 = C(R15)CH2-R23, OH, OR26, OC(=0)R27, R26, COOH, C(=0)OR26, CHOHCH2OH, CHOHCH2OR26, CHOHCH2OC(=0)R27, CH2CH2OH,CH2CH2OR26, CH2CH2OC(=0)R27, CH2CN, CH2N3, CH2NH2, CH2NHR26, CH2N(R26)2, CH2OH, CH2OR26, CH2 0(C=0)R27, CH2 0(P=0) (OH)2, CH2 0(P=0) (OR26)2, CH2SH, CH2S-R26, CH2SC(=0)R27, CH2NC(=0)R27, C(=0)CHR28OH, C(=0)CHR28OR26, C(=0)CHR28OC(=0)R27 or R10 and R25 taken together may be =C(R28)2, that is, an optionally alkyl substituted methylene group;
wherein R26 = C1-C6 (alkyl, branched alkyl, cycloalkyl, haloalkyl, aralkyl, aryl);
R27 = R26 + OR26; R28 = H, C1-C6 (alkyl, branched alkyl, cycloalkyl).
8. The method of Claim 6 wherein the other compound which lowers IOP
is selected from the group consisting of miotics, sympathomimetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins.
is selected from the group consisting of miotics, sympathomimetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins.
9. The method of Claim 7 wherein the other compound which lowers IOP
is selected from the group consisting of miotics, sympathomimetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins.
is selected from the group consisting of miotics, sympathomimetics, beta-blockers, carbonic anhydrase inhibitors, and prostaglandins.
10. A method for lowering and controlling IOP which comprises administering to an affected eye, a composition comprising a pharmaceutically effective amount of both 4,9(11)Pregnadien-17 ,21-diol-21-acetate and a beta-blocker selected from the group consisting of timolol, betaxolol, and levobetaxolol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/031557 WO2002040030A1 (en) | 2000-11-16 | 2000-11-16 | Combination therapy for lowering and controlling intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2428799A1 true CA2428799A1 (en) | 2002-05-23 |
Family
ID=21742004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002428799A Abandoned CA2428799A1 (en) | 2000-11-16 | 2000-11-16 | Combination therapy for lowering and controlling intraocular pressure |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1341541A4 (en) |
| JP (1) | JP2004522711A (en) |
| AU (2) | AU2001217709B2 (en) |
| CA (1) | CA2428799A1 (en) |
| WO (1) | WO2002040030A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| ATE517908T1 (en) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | ANDROSTAN-17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS |
| TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| CN108066283B (en) * | 2017-12-28 | 2020-03-24 | 兆科（广州）眼科药物有限公司 | Preparation method of levobetaxolol hydrochloride eye drops |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| US4904649A (en) * | 1986-05-23 | 1990-02-27 | New England Medical Center Hospitals, Inc. | Method and solution for treating glaucoma |
| WO1987007141A1 (en) * | 1986-05-23 | 1987-12-03 | New England Medical Center Hospitals, Inc. | Method for treating glaucoma |
| US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5153192A (en) * | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
| US5153193A (en) * | 1991-10-01 | 1992-10-06 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
| CA2425849C (en) * | 1991-11-22 | 2007-02-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| NZ506921A (en) * | 1998-04-07 | 2002-02-01 | Alcon Lab Inc | Gelling ophthalmic compositions containing xanthan gum |
| WO2000018316A2 (en) * | 1998-09-25 | 2000-04-06 | Alcon Laboratories, Inc. | Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
-
2000
- 2000-11-16 CA CA002428799A patent/CA2428799A1/en not_active Abandoned
- 2000-11-16 AU AU2001217709A patent/AU2001217709B2/en not_active Ceased
- 2000-11-16 WO PCT/US2000/031557 patent/WO2002040030A1/en not_active Application Discontinuation
- 2000-11-16 AU AU1770901A patent/AU1770901A/en active Pending
- 2000-11-16 EP EP00980450A patent/EP1341541A4/en not_active Ceased
- 2000-11-16 JP JP2002542403A patent/JP2004522711A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004522711A (en) | 2004-07-29 |
| AU2001217709B2 (en) | 2005-10-13 |
| AU1770901A (en) | 2002-05-27 |
| EP1341541A1 (en) | 2003-09-10 |
| WO2002040030A1 (en) | 2002-05-23 |
| EP1341541A4 (en) | 2004-11-17 |
| WO2002040030A8 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2001936C (en) | Methods and compositions for controlling ocular hypertension with angiostatic steroids | |
| US6441047B2 (en) | Combination therapy for treating glaucoma | |
| JP3719609B2 (en) | Use of certain isoquinoline sulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
| US5811446A (en) | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor | |
| US6172054B1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
| JP2009029828A (en) | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER | |
| JP4482726B2 (en) | Glaucoma treatment agent comprising Rho kinase inhibitor and prostaglandins | |
| CA2189424C (en) | Non-steroidal anti-inflammatory ophthalmic suspensions | |
| WO2000054810A1 (en) | Combination therapy for treating glaucoma | |
| AU704938B2 (en) | Combination therapy for treating glaucoma | |
| JPH05194271A (en) | Topical ophthalmic composition | |
| CA2428799A1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
| AU2184499A (en) | Ophthalmic composition | |
| TW201726146A (en) | Aminophosphinic derivatives for preventing and treating ocular pain | |
| JP2965267B2 (en) | Topical anti-glaucoma composition | |
| AU2001217709A1 (en) | Combination therapy for lowering and controlling intraocular pressure | |
| AU2006200143B2 (en) | Combination therapy for lowering and controlling intraocular pressure | |
| CA1338519C (en) | Antiglaucoma compositions containing combinations of sympathomimetic agents and beta-1 selective beta-blockers | |
| EP0608604A1 (en) | Ajmaline to reduce elevated intraocular pressure | |
| EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
| EP0277814B1 (en) | Anti-glaucoma use of trifluoromethanesulfonamide | |
| AU2004214563A1 (en) | Combination therapy for treating glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |